Wed, Apr 23, 2014, 9:56 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Astex Pharmaceuticals, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • merohricht merohricht Nov 14, 2012 12:56 PM Flag

    Presentation Today

    Don't know why they would understated earnings! Why do they want share price to be under $2 after Manuso says he is focusing now on shareholders? I think he loses more credibility if they blow away earnings. Hopefully Eiasi says something about 2013 Dacogen earnings.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Hopefully Eiasi says something about 2013 Dacogen earnings.

      Mero, Eisai has so many products and dacogen a like 1/20 of there revenue, its not a big thing for dacogen revenue to be cut in half say 350mil to 175mil but for astx that goes from 70mil to less than 35mil and with the spending escalating with stock compensation, blowup on aisle 8. Why couldn't we sell the rights just like dacogen, we dont have a sales team, we've been doing this to all of our other drugs. Manuso is a dingbat for being inconsistant. SGI-110 shows promise, better than dacogen according to today's conference, so why not get 15 to 20 million up front and milestones. Aren't we paying for the the other trials that sgi-110 is in like overian cancer.

      • 1 Reply to lovinfriendship
      • Lovingfriendship,

        Eisai forecasts Dacogen sales in the past and I believe they will continue to do so in the future. I think Man uso is doing one thing right by continued s110 development and negotiating a better deal than 20 million payment and 20 to 30% totality payment. What I am concerned about is the ineptness of this company getting anything done or approved. I have other concerns but it sounds like complaining. When considering s110 benefits, remember Dacogen and Vidaza patient improvement when they increased dose from 3 to 5. Also I have gotten more information from Eiasi and even Celg than I do from Astex.

    • Mero
      Big earnings beats move stocks happens everyday. The trick is too under promise and over deliver the exact reverse of whats happened in the past here. And most importantly maybe they want one more set of cheap options this year. Why start mentioning generic Dacogen now at the last minute when the patent date has always been there.

      Look I feel your frustration and while Dr M has been prudent in managing the burn he has been horrible in many other area's chief of which is wall street credibility . But I disagree with your characterization that its all worthless. Its certainly not. My question is if you own this stock ...why?
      if you feel so negative on everything

8.4950.000(0.00%)Oct 10 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.